Described is a method of manufacturing carboxymethyl cellulose (CMC) fibres containing an antimicrobial, the fibres being suitable for use in the preparation of wound dressings, wherein the antimicrobial is selected from the group consisting of a biguanide, a biguanide derivative, octenidine, taurolidine, and a combination of two or more thereof, the method comprising, submerging CMC fibres comprising at least 95 wt % carboxymethylcellulose on a dry weight basis in a treatment solution for a duration adequate to provide the CMC fibres containing an antimicrobial, the treatment solution comprising the antimicrobial and at least 70 wt % of a water-miscible organic solvent selected from C.sub.1-C.sub.4 alkanols, C.sub.3-C.sub.5 ketones, and a combination of two or more thereof. Anti-microbial CMC fibres obtained by the methods and wound dressings containing such fibres are also described.

Methods of treating or ameliorating multiple sclerosis by the dihydroorotate dehydrogenase (DHODH) inhibitor vidofludimus or a pharmaceutically acceptable salt and/or a solvate, in particular a hydrate, thereof or a solvate, in particular a hydrate, of a pharmaceutically acceptable salt thereof, by administering to a human patient a therapeutically effective amount of the DHODH inhibitor, more specifically a daily dose of about 10 mg to about 45 mg.

Methods of treating or ameliorating multiple sclerosis by the dihydroorotate dehydrogenase (DHODH) inhibitor vidofludimus or a pharmaceutically acceptable salt and/or a solvate, in particular a hydrate, thereof or a solvate, in particular a hydrate, of a pharmaceutically acceptable salt thereof, by administering to a human patient a therapeutically effective amount of the DHODH inhibitor, more specifically a daily dose of about 10 mg to about 45 mg.

The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

Methods of forming a gel and related methods of treating subjects with such gels are described. The method may include preparing a composition by combining a macromer comprising a first polyethylene glycol (PEG)-based polymer, a poly(ethylenimine)-based polymer, or a poly(1,2-glycerol) carbonate-based polymer, the macromer including at least one first functional moiety, a crosslinking agent comprising a second PEG-based polymer that includes at least one second functional moiety, and a photoinitiator, and activating the photoinitiator via a light source to form the gel.

Methods of forming a gel and related methods of treating subjects with such gels are described. The method may include preparing a composition by combining a macromer comprising a first polyethylene glycol (PEG)-based polymer, a poly(ethylenimine)-based polymer, or a poly(1,2-glycerol) carbonate-based polymer, the macromer including at least one first functional moiety, a crosslinking agent comprising a second PEG-based polymer that includes at least one second functional moiety, and a photoinitiator, and activating the photoinitiator via a light source to form the gel.

The present invention relates to large scale manufacture of nanoscale microsheets for use in applications such as wound healing or modification of a biological or medical surface.

The present invention relates to large scale manufacture of nanoscale microsheets for use in applications such as wound healing or modification of a biological or medical surface.

Provided are a cognitive function improving agent effective for improving cognitive function such as memory and learning ability, and a method for evaluating or selecting the cognitive function improving agent. The cognitive function improving agent comprises a GIP function inhibitor as an active ingredient.